Clinical Research Directory
Browse clinical research sites, groups, and studies.
Targeting Orexin to Treat Nicotine Dependence
Sponsor: Mclean Hospital
Summary
Tobacco smoking continues to be the primary cause of preventable mortality in the United States. Despite the availability of smoking cessation aids, the majority of those trying to quit smoking end up relapsing. Thus, there is a strong need to evaluate alternative treatment targets such as orexin antagonists, which have shown promise in preclinical models at reducing the motivational aspects of drug use.The current work will evaluate the influence of orexin antagonism on several factors impacting the motivation to smoke.
Key Details
Gender
All
Age Range
18 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
4
Start Date
2019-09-26
Completion Date
2023-07-31
Last Updated
2026-09-21
Healthy Volunteers
No
Conditions
Interventions
Suvorexant 20 mg
Suvorexant at a high dose (20 mg)
Suvorexant 10 mg
Suvorexant at a low dose (10 mg)
Placebo oral tablet
Placebo
Locations (1)
McLean Hospital
Belmont, Massachusetts, United States